Oriola Oyj

DB:O5O Stock Report

Market Cap: €166.0m

Oriola Oyj Valuation

Is O5O undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of O5O when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: O5O (€0.9) is trading below our estimate of fair value (€1.3)

Significantly Below Fair Value: O5O is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for O5O?

Key metric: As O5O is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for O5O. This is calculated by dividing O5O's market cap by their current revenue.
What is O5O's PS Ratio?
PS Ratio0.1x
Sales€1.63b
Market Cap€166.05m

Price to Sales Ratio vs Peers

How does O5O's PS Ratio compare to its peers?

The above table shows the PS ratio for O5O vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average0.4x
ILM1 Medios
0.2x6.1%€325.0m
HAEK HAEMATO
0.3xn/a€60.6m
MED MEDICLIN
0.2x0.7%€121.6m
M12 M1 Kliniken
0.9x8.2%€293.2m
O5O Oriola Oyj
0.1x4.8%€166.0m

Price-To-Sales vs Peers: O5O is good value based on its Price-To-Sales Ratio (0.1x) compared to the peer average (0.4x).

Price to Sales Ratio vs Industry

How does O5O's PS Ratio compare vs other companies in the DE Healthcare Industry?

1 CompanyPrice / SalesEstimated GrowthMarket Cap
TLIK Arzneiwerk VIDA
0.08xn/aUS$4.90m
No more companies available in this PS range
O5O 0.1xIndustry Avg. 0.6xNo. of Companies3PS00.40.81.21.62+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: O5O is good value based on its Price-To-Sales Ratio (0.1x) compared to the European Healthcare industry average (0.6x).

Price to Sales Ratio vs Fair Ratio

What is O5O's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

O5O PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.1x
Fair PS Ratio0.3x

Price-To-Sales vs Fair Ratio: O5O is good value based on its Price-To-Sales Ratio (0.1x) compared to the estimated Fair Price-To-Sales Ratio (0.3x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst O5O forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€0.90
€1.03
+14.5%
2.4%€1.05€1.00n/a2
Nov ’25€0.90
€1.03
+14.4%
2.4%€1.05€1.00n/a2
Jul ’25€0.90
€1.05
+16.4%
4.8%€1.10€1.00n/a2
Jun ’25€0.93
€1.08
+15.1%
7.0%€1.15€1.00n/a2
May ’25€0.98
€1.13
+14.8%
2.2%€1.15€1.10n/a2
Apr ’25€0.99
€1.18
+18.2%
2.1%€1.20€1.15n/a2
Mar ’25€1.09
€1.18
+7.8%
2.1%€1.20€1.15n/a2
Feb ’25€1.08
€1.18
+8.6%
10.6%€1.30€1.05n/a2
Jan ’25€1.06
€1.18
+11.3%
10.6%€1.30€1.05n/a2
Dec ’24€1.03
€1.18
+14.1%
10.6%€1.30€1.05n/a2
Nov ’24€0.93
€1.18
+26.9%
10.6%€1.30€1.05€0.902
Oct ’24€0.91
€1.18
+29.8%
10.6%€1.30€1.05€0.912
Sep ’24€0.93
€1.18
+26.1%
10.6%€1.30€1.05€0.932
Aug ’24€1.09
€1.28
+16.8%
2.0%€1.30€1.25€0.962
Jul ’24€1.26
€1.60
+27.4%
6.3%€1.70€1.50€0.902
Jun ’24€1.34
€1.60
+19.0%
6.3%€1.70€1.50€0.932
May ’24€1.43
€1.60
+11.6%
6.3%€1.70€1.50€0.982
Feb ’24€1.73
€2.23
+29.2%
7.6%€2.40€2.00€1.083
Jan ’24€1.71
€2.27
+32.9%
5.5%€2.40€2.10€1.063
Dec ’23€1.77
€2.27
+28.4%
5.5%€2.40€2.10€1.033
Nov ’23€1.83
€2.33
+27.4%
7.3%€2.50€2.10€0.933

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

Shandong Weigao Group Medical Polymer

HK$20.6b

Engages in the research and development, production, wholesale, and sale of medical devices in the People’s Republic of China.

UK2

HK$0.53

7D

-0.9%

1Y

-35.8%

Top Glove Corporation Bhd

RM 7.8b

An investment holding company, manufactures, trades in, and sells gloves in Malaysia, Thailand, the People’s Republic of China, and internationally.

5OU

RM 0.98

7D

0.5%

1Y

-82.5%

OrbusNeich Medical Group Holdings

HK$3.1b

An investment holding company, researches, develops, manufactures, trades in, sells, and markets medical devices/instruments used for the treatment of coronary and peripheral vascular diseases in Japan, Europe, the Middle East, Africa, the Asia Pacific, the People’s Republic of China, and the United States.

Q8T

HK$0.40

7D

-21.2%

1Y

-46.9%